Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Optifit is the first clinically validated therapeutic bra and fitting system, promoting a balanced posture, reducing musculoskeletal health problems associated with larger bust sizes. Optifit provides a proven alternative to breast reduction surgery
Overview of Innovation:
The OptiFit bra and measurement system, designed by a Consultant Plastic & Reconstructive surgeon with bespoke manufacturing in the UK. www.optifitbra.com
  • Ensures an effective and comfortable ‘bespoke’ fit
  • Significantly reduces trauma and pain in Thoracic and Lumbosacral regions
  • Prevents overstretching of the suspensory ligament reducing the chance of stretch marks.
  • Preserves body shape
  • Maintains healthy posture, relieving pressure on diaphragm and balance pelvis
  • Reduces risks of tissue maceration, intertrigo and fungal growth
It is estimated that 70% of women wear the wrong size bra. The traditional alphabet bra size measurement system was initially only established for cup sizes A-D, but with 40% of British females measuring a D cup or above the same level of fit and support is not achieved in larger sizes. Failure to support the breasts can lead to many physiological conditions including back and breast pain.
 
Inappropriately sized and positioned back straps cause existing bras to slide away from the breasts reducing support. It is estimated that 70% of women wear poorly fitting bras and that 99% of women with large breasts wear the wrong size bra.  Professionally fitted bras are often as poorly fitted as ‘off the shelf products.
 
Bras that do not support the breast correctly cause many skin problems. If the weight of the breasts is mostly supported by the shoulder straps, these can dig in and cause angry red welts to develop.
Underwired bras push into the tissue leading to lesions, marks and sores.
Optifit bras do not use underwires. They hold the breast in its natural position away from the body preventing the above problems.
If the breasts are not supported away from the ribs, rubbed skin, maceration, intertrigo and fungal infections can develop underneath.
 
what_is-1.png     what_is-2.png     
 
Summary of interim research study findings -
  • Can help patients with Back pain
  • Can obviate need for breast reduction surgery in many patients
  • Is a cure for Inframammary intertrigo
Can potentially help patients with mastalgia especially those with associated shoulder girdle dysfunction
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
How best to allocate surgical resources and time within the NHS is a problem with which we wrestle and disagree constantly. Reduction mammaplasty is surgery rationed in NHS practice, yet evidence suggests that those who undergo it derive significant improvements in physical health and quality of life.
 
NHS recommends professionally fitted bras prior to Breast reduction surgery but has not evaluated their efficacy.
 
Many women do not fulfill the criteria for surgery e.g. high BMI.  Such patients have nowhere to go and are a burden on the NHS, requiring drugs for back pain, intertrigo etc. Furthermore, women with high BMI’s cannot find a properly fitted bra. The Optifit bra will help such patients and overall reduce the need for breast reduction surgery. Women seeking reduction mammaplasty often wear ill-fitting bras and are therefore likely to exacerbate some of their presenting symptoms as a result. Women may wait years from referral to surgery and symptom relief. A correctly fitted bra alleviates symptoms and may even remove the need or wish for surgery.

Savings from reduced surgical intervention and associated consultations, imaging and follow ups will be enormous, (‘21,328 procedures were carried out between 2006 and 2011, some on girls as young as 15 -which, at £5,000 each, cost taxpayers more than £106 million’. (Daily Mail July 2014)).
 
Back Pain: OptiFit should be a 1st line treatment for LBP in women with high BMI’s and/or large breasts.  A systematic review on global prevalence of LBP the highest prevalence showed women aged between 40-80 (incidence 11.9%  http://www.ncbi.nlm.nih.gov/pubmed/22231424). The OptiFit intervention would help many patients and demonstrate significant savings for the NHS
 
Intertrigo: A direct result of friction between two skin surfaces. With poorly fitted bras there is a mismatch between cup/cradle diameter and breast base.  Patients I see regularly in my clinic have had several ‘Professional’ fittings and still cannot find the correct size bra. With it’s unique design the Optifit bra remains in the inframammary crease (however large the breast and BMI may be) and it is therefore impossible to get intertrigo
 
Mastalgia: Incidence of mastalgia in the general population is reported as over 60% http://www.ncbi.nlm.nih.gov/pubmed/9240595  Most women who attend Breast Clinics with breast pain also have musculoskeletal pain related to breast size.  The 1st line of treatment for mastalgia is a professionally fitted bra
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
The savings resulting from reduced surgical intervention and the associated consultations, imaging and follow up will be enormous, (‘21,328 procedures were carried out between 2006 and 2011, some on girls as young as 15 - which, at £5,000 each, cost taxpayers more than £106 million’. (Daily Mail July 2014)). In addition the benefits in QALY outcome measures for women will also be substantial.
 
Back Pain: We feel that this product should be recommended as a first line treatment for low back pain in women with high BMI’s and/or large breasts.  In a systematic review on the global prevalence of the low back pain in the world the highest prevalence was noted to be in women between the age of 40-80.  The incidence was found to be 11.9%  http://www.ncbi.nlm.nih.gov/pubmed/22231424 .. This simple intervention should help many patient and save the NHS on many interventions.
 
Inframammary Intertrigo:It is difficult to comment on the incidence of inframmary intertrigo in the general population as there is not ICD-10 or ICPC score.   Intertrigo is a direct result of friction between two skin surfaces.  This is due to a poorly fitted bra as there is a mismatch between the cup/cradle diameter and the breast base ( the breast base in patients with high BMIs can be several centimetres more than the cup/cradle diameter in professionally fitted bras).  The patients I see regularly in my clinic with intertrigo have had several fittings and still cannot find the correct size bra as it simply does not exist for them. With its’ unique design the optifit bra, however, stays at the inframammary crease( however large the breast and BMI may be) and it is simply not possible to get intertrigo.
 
Mastalgia: The incidence of mastalgia in the general population has been noted in studies to be over 60%.  http://www.ncbi.nlm.nih.gov/pubmed/9240595 .   Most women who attend Breast Clinics with breast pain also have musculoskeletal pain related to breast size.  The first line of treatment for mastalgia is a professionally fitted bra.
Current and planned activity: 
Ongoing research studies at University of Central Lancashire:
  • Exploring the OptiFit bra solution against fashion industry standards
  •  To determine the initial and short term biomechanical effects on posture when wearing the OptiFit bra compared to the standard or usual bra, in individuals with back or neck pain.
  • To determine the initial and short term effects on breast health, pain, activity and comfort when wearing the OptiFit bra compared to the standard or usual bra, in individuals with back or neck pain 
Required studies:
  • A community based study of incidence of inframammary intertrigo in general population resulting from poor bra fitting
  • A comparative efficacy study is required for surgical and non surgical management of symptomatic macromastia
  • Health Economics cost benefits analysis of surgical vs non surgical intervention
Further trial partners required to evaluate the product and measurement system
What is the intellectual property status of your innovation?:
Patent for Bra (GB2362560B): The granted patent has four independent claims. These are (claim 1) which covers the bra itself,  (claim 7) which covers a method of fitting a bra according to the invention, (claim 10) which covers a range of bras according to your invention and (claims 11 and 12) which cover a bra and method of making a bra respectively with particular emphasis on the back portions.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Atul Khanna 29/04/2016 - 12:18 Publish 2 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Lilie EPR captures outpatient activity, diagnoses and treatments for GUM patients, provides the team shared access to patient records enabling instant communication between the service, lab and patient; reducing costs with efficient data management.
Overview of Innovation:
Leading the way  in the Management of Sexual Health Services
The modern day sexual health service challenges are significant. Public Health England (PHE) indicate that there were 446,253 sexually transmitted infections diagnosed in England in 2013 with Chlamydia being the most common, making up 47 per cent of all diagnosed cases. The most expensive cost to the NHS is HIV Infection, each new case of HIV infection is estimated to represent between £280,000 & £360,000 in lifetime treatment costs. Although the fall in teenage pregnancy is one of the success stories of the last decade in the public health field. However there is always room for improvement especially with more sexually active young people.
 
Lilie provides Sexual Health clinics and HIV services with a comprehensive Sexual Health computer software solution. Lilie is a fully scalable Electronic Patient Record system (EPR) used to capture outpatient activity, referrals, diagnoses and treatments for genitourinary medicine (GUM) patients. Having all the patients’ data in one EPR system provides all the clinic team members with fast access to patient data greatly reducing administration functions. All audit and quality measures are incorporated automatically reducing clinical risks and improving the quality of sexual health services.

Lilie’s core is the base application which is a totally secure full EPR system with comprehensive patient communication, statutory reporting i.e. HARS, SRHAD and GUMCAD, adhoc report generation. Additional modules to the core system can be purchased allowing the client to meet their budgetary requirements. Additional modules include: Contraceptive & Reproductive Health which is a secure and efficient way to manage Contraceptive and Reproductive Health data and services/ Chlamydia Screening providing exceptional NCSP data capture and reporting facilities/ Prescribing which includes the Dictionary of Medicines and Devices (DM+D)/ SMS Texting is an effective way to improve patient communications and reduce DNA rates/ Touchscreen allows the patient to announce their arrival in clinic and discretely enter personal data/ Internet Booking to empower your patients with time-saving, secure appointment management/ Lab Communications for fast and secure ways to order laboratory tests and receive results/ Collect for collecting patient data using mobile devices within an outreach environment.


For more information visit http://6pmsolutions.com/products/clinical/lilie
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Improves Productivity
Lilie is intuitive and easy to use allowing clinicians to spend more quality time with patients whilst allowing clinics to reduce appointment, management and reporting times. By default, the patients’ previous responses to questions are automatically populated hence saving clinic time and improving patient care.

Speeds up data collection.
The patient data you collect during your general working day is input into the electronic patient record (EPR) easily. The software and the dynamic screens change, validate and evolve as you enter this data.   

Reduces DNA’s
Lilie Online Internet Booking offers patients a discreet, more convenient and alternative route to treatment without staff intervention reduces management costs.  Lilie discrete SMS Text messaging will send out appointment reminders giving the patient the ability to confirm or cancel an appointment, freeing up slots for other patients.


Ensures clinical safety and maximises patient convenience.  
Lilie displays a patient banner across the top of the screen displaying key patient information, ensuring clinical safety whilst speeding up the clinic consultation.

Intuitive and easy to use. 
Lilie allows clinics to be more flexible according to their own services requirements. The consultation screens are easy to use and patient data can be easily collected. Lilie is so intuitive, you will reduce your training needs.

Ensures accurate recording of data. 
Data is input during the consultation whilst ensuring the right questions are asked at the right time, reducing and removing transcription errors. Thus written notes and illegible hand writing are a thing of the past.  

Accessible anywhere.
Lilie is available on a web based N3 platform and the cloud allowing access to different users over the Internet. This ensures improved availability, no costly client installations and access from any trust computer or device.

Simplified deployment, maintenance and painless upgrades.
The Lilie hosted solution can be deployed quickly and easily since no client terminal installation is required. Drastically reducing the initial investment in IT infrastructure.
The hosted solution ensures software updates and backups are carried out “behind the scenes”, reducing the costs associated with client installations and reducing the involvement of IT department resources.  This also means that when the number of users increase, no further investment in hardware, bandwidth or resources is required.
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The Best outcomes for people and for populations depend on effective collaboration and cooperation. We can get there faster with Lilie’s integrated working tools.

Nationally, around four million people per year use NHS contraception services. The number of visits to genito-urinary medicine (GUM) clinics has doubled over the last decade and now stands at over a million a year.  The economic climate and pressure on resources are encouraging everyone to explore new approaches and opportunities that can deliver better outcomes and better value. The fields of sexual health, sexually transmitted infection (STI), contraception, reproductive health and HIV are frequently talked about as a whole service, yet each is separate and has its own defining features. Different elements have different commissioning arrangements which add to the complexity.

Lilie EPR for sexual health has been designed specifically to support multi-disciplinary teams treating sexual health and HIV. This “whole system” approach makes sense to the service user, the community and the commissioner. Having patient data in an EPR system provides all clinic team members with fast access to patient records, greatly reducing administration functions. Unlike paper records, patient data can be accessed from any Trusts computer enabling more than one healthcare professional to access the same record at the same time.  Patients’ needs for integrated pathways are at the heart of the case for whole system commissioning. Poorly connected care increases the risk of service users falling out of the system which can reduce their treatment adherence and worsen subsequent health outcomes. Disjointed pathways also result in missed opportunities to address people’s wider needs.

‘Lilie is a complete comprehensive software system that manages; Sexual Health, Contraceptive, HIV and Reproductive Health services.  There is also a separate module for contraception, so as to provide ‘Services’ with a choice of modules depending on their requirements.’

Greater adoption of this technology would also allow our company to develop additional modules for this system, as well as expand our team here in the region.

Lilie is the market leading Sexual health software in the UK
Current and planned activity: 
Lilie is constantly being evaluated to ensure it meets the demands of the users.  The software roadmap is ever evolving and this is helped by the Lilie User groups where nearly 200 users attend annually.

A new version of Lilie is being released where dynamic forms will feature heavily.  For more information contact lilie@6pmplc.com.



Planned / required activity 
  • Procurement / Adoption: -  We would like to see greater regional adoption of our Lilie and integrated suites of products and modules
  • Trials - We are interested in discussing opportunities with Trusts for additional trials, evaluation and validation of our system 
What is the intellectual property status of your innovation?:
Lilie is owned by 6pm Group.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Joanne Shrimpton 16/06/2016 - 15:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Levo® Therapy System is an innovative sound based therapy designed for use during sleep. The system creates and delivers a personalised sound therapy that uses the brain’s natural plasticity to reduce symptoms and provide relief long term.
Overview of Innovation:
Tinnitus is a conscious awareness of a sound in the ears or head that is not due to an external noise. Every individual has their own very personal tinnitus tone. It can be a high or low frequency sound and its volume can vary over time. An estimated seven million people in the UK have experienced tinnitus at one time or another.
 
People living with tinnitus report that their condition limits their social life, their relationships and their opportunity to work (source: British Tinnitus Association patient website https://www.tinnitus.org.uk/).
 
Levo® Therapy System for Tinnitus is an FDA cleared and CE approved sound-based therapy which works with the brain’s natural plasticity to help the brain to get used to, or habituate, to the tinnitus sound within the hearing centre of the brain.
 
Levo® is specifically designed to be used during sleep when our brains are more prone to be responsive to sound therapies that strive to change brain activity patterns. The system enables patients to map their specific tinnitus sound, or ‘sound print’, to create a personalised sound therapy.
 
The personalised therapy sound is presented to the patient while they are asleep via an iPod device using a tailor-made proprietary ear phone system which is designed to be slept in (Levo® will switch itself off automatically during the night once the correct dosage has been applied). This stimulates the hearing centre of the brain with the goal to encourage habituation to the tinnitus sound and reduce the perceptual loudness / annoyance of the tinnitus signal. Improvements in tinnitus symptoms are tracked over time, which is motivating for the patient and provides useful guidance for the clinician.
 
The Tinnitus Clinic is suitable for patients with atonal or tonal tinnitus, or a mix of frequencies from less than 200Hz right through to beyond 10,000Kz. Levo® System therapy is a prescriptive approach which requires a single course of treatment over a period of 30-60 days.  Patients self-administer Levo® therapy during their night time sleep cycle and can carry on their normal daily life without disruption, including wearing hearing aids for hearing loss during the day if required.  Attendance at a clinic for follow up visits is usually one or two visits only.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
Currently NHS management of patients with tinnitus can require clinic & GP attendance over a period of years alongside self-management techniques with treatment involving devices (hearing aids/sound generators) & counselling strategies aimed at reducing the negative emotional impact of the condition.
 
The Levo Therapy System provides a prescriptive pathway of treatment delivered by audiologists or hearing aid dispensers reducing the need for a multidisciplinary approach & freeing up time for healthcare professionals (GP's/audiologists/psychologists). Successful treatment with Levo Therapy would mean patients do not need to revisit GP/audiology/ENT services. It also has the additional effect of improving the patient’s emotional state without the need for psychodynamic intervention/pharmacotherapy delivering a cost saving advantage for the health service.
 
Using the NHS Reference cost schedule 2010-11 the conceptual (comparator) & the intervention (Levo Therapy model) have been costed.
 
An average patient receiving Levo Therapy will receive the device once in their lifetime at which point their tinnitus is managed & does not return, i.e. successfully habituates. The cost of the Levo Therapy pathway in the private sector is currently £4225 over a patient’s lifetime.
 
In comparison when looking at the average cost of the comparator arm of the technology which is the usual pathway for NHS tinnitus treatment, the weighted average lifetime cost per patient for these individuals is £8414.
 
Therefore for patients with a THI level 3 & above Levo Therapy generates savings of £4189 per patient when comparing NHS costs to private sector costs that include the service, fitting & follow up charges.
 
The weighted average cost is based on the multitude of resources required to manage tinnitus under the comparator technology over a patient’s lifetime such as:
  • Most patients require 2 digital hearing aids which need to be replaced every 5 years at a lifetime cost of about £1200 per patient, cost includes an assessment & fitting for each replacement
  • Digital hearing aids require continuous follow up appointments/repairs at a lifetime cost of about £4300 per patient
  • Most patients using hearing aids won't have their tinnitus managed & therefore will require a session of MTRT or CBT at a lifetime cost of about £580-£1200 respectively per patient per treatment
  • Once MTRT &/or CBT are successful patients will require counselling to sustain their tinnitus treatment at a lifetime cost of about £2533 p
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Hearing is central to our health & wellbeing. Hearing problems are a growing challenge across society & will become even bigger over the next decade due to the growing ageing population & increased exposure to workplace & social noise such as MP3 players.
 
It is estimated between 10-15% of adults will have tinnitus with 3% likely to require a clinical intervention for their tinnitus*. Reported prevalence of tinnitus varies from 12-36% & is more common in children with hearing loss compared to children with normal hearing. Like adults most children self-manage but a proportion require further support.*"
 
In some sections of the population tinnitus is statistically more significant for example 11% of veterans that were surveyed reported having problems hearing & 6 % reported tinnitus.**
 
Statistics show a higher incidence of tinnitus amongst UK Armed Forces than the general population^ & with the Royal Centre for Defence Medicine located at University Hospitals Birmingham NHS Foundation Trust & the HQ of the Surgeon General & the Joint Medical Command in Lichfield the regions Service community could benefit from access to the Levo Therapy System.
 
According to the Department of Health (2011) mental health problems are the largest single source of disability accounting for 23% of the total disease burden.*** The innovative ‘RAIDPlus integrated mental health urgent care test bed’ project highlights the region’s commitment to providing services for people with mental health illness.
 
Tinnitus is associated with a higher occurrence of depression than the general population (Holmes and Padgham 2009). Daugherty (2007) suggests at least 40-60% of patients with tinnitus also have a major depressive disorder, which often worsens their perception of the condition.***
 
For patients with tinnitus who have a depressive disorder The Levo Therapy System can improve emotional health & in turn the patient’s quality of life whilst reducing the burden on the health system.
 
* Davis, A, El Refaie, A (2000) “The epidemiology of tinnitus” in R Tyler (ed.) The Handbook of Tinnitus. Singular, pp 1 -23
** The Royal British Legion Household Survey 2014, November 2014.
https://www.actiononhearingloss.org.uk/supporting-you/policy-research-an...)
*** Hearing Loss, Tinnitus & Mental Health https://www.actiononhearingloss.org.uk/mentalhealth.aspx
*" https://www.england.nhs.uk/wp-content/uploads/2016/07/HLCF.pdf
^ https://www.cobseo.org.uk/british-tinnitus-association/
Current and planned activity: 
The Tinnitus Clinic is supporting the grants department of the Royal British Legion by raising awareness of access to the Hearing Fund for individuals with a military background whose tinnitus could benefit from treatment from Levo Therapy System.

The Tinnitus Clinic would welcome discussions with either military rehabilitation providers, CCG’s or Primary Health Care to test the use of Levo Therapy in their locations.

ROI would be with new patients within the first 6 months but could also be introduced as a disruption to current patients on treatment, allowing savings to be implemented even with patients further along the care pathway.
What is the intellectual property status of your innovation?:
Product Manufacturer Otoharmonics has two issued patents in the US and these patents are in the European National Phase Application No. 14818503.6.  Additionally, Otoharmonics has a patient pending for “Wireless Audio Device”.  “Levo” and “Otoharmonics are also Trademarked in the UK/EU.
Levo System is CE Mark Class IIa approved.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
The Levo Therapy is currently only available in the private sector. Ideally, we would like tos cale up by providing the treatment to NHS audiology departments, or primiary care practices with community audiologists. 
Measures:
Quality: CE and FDA approved QM systems ensure device quality. Patient experience is gathered through surveys and completion of Tinnitus Fuinctional Index questionnaires at the start and completion of treatment
Safety:  Safety is the role of the FDA and CE registration and we comply with manufacturers requirements for reporting adverse incidents , of which we have had none. 
Cost: The Levo Therapy costs £3995 inclusive of VAT in the private sector but this would not be cost price to an NHS commissioner
People: Quality of Life measures using the TFI recording. Suibjectgive measures during follow up appointments 
Adoption target:
The Levo Therapy is available privately and we would welcome the opportunity to provide this system to severe or catastophic patients within the NHS syetem, who are suitable for this treatment and have not responded to current NHS treatments. 
Read more
Hide details
Josephine Swinhoe 26/04/2017 - 11:21 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
MIRA is a software application designed to make physiotherapy fun and convenient for patients in need of rehabilitation. It turns physical exercises into video-games and uses Microsoft Kinect to track and assess patient treatment compliance.
 
Overview of Innovation:
Physiotherapy and rehabilitation can be a long, difficult and sometimes painful process. Treatment plans can be cumbersome and a slow recovery can be disempowering for patients. 70% of patients do not adhere to home exercises, which increases the total time needed for recovery, leading to higher costs for the healthcare sector.

MIRA displays these exercises as video-games and asks patients to complete the recommended movements to progress through each game level. As a result, patients are playing, while at the same time actually recovering. The patient’s performance data is also tracked, storing all the repetitions, improvements or issues for the therapists to adapt the treatment accordingly. As each patient and their treatment require careful planning, MIRA is designed as a tool for the therapists, to enable specialists to customise the treatment for each individual. Our innovative software can be tailored to the patient’s condition, needs and goals (stroke, falls prevention, MSK disorders etc.), using off-the shelf hardware (laptop/PC and motion sensor).

The software application is registered as a Class I Medical Device in Europe (CE Mark) and can be installed in any clinical environments where patients go for their regular treatment sessions, as well as at home where patients can be remotely monitored by their therapists. This allows the patient to exercises at home under the remote supervision of a healthcare provider. Furthermore, MIRA reduces costs by supplementing staff and reducing waiting times, as well as by decreasing the necessary number of clinic visits and the travel costs associated to them.

The system runs on Windows PCs, using Microsoft Kinect, a mainstream motion capture camera, to engage and track patients throughout their treatment.

MIRA Rehab has 14 UK institutions and another 44 worldwide, helping 600 patients monthly.  The youngest patient to have ever used the system was 3 years old, while the oldest is 102. MIRA was recently featured on BBC, as well as on TED.com in 2015.












www.mirarehab.com

Video links:
MIRA – Play your way to recovery
MIRA – Helping older people regain their mobility
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Person centred care
Benefit to NHS:
The primary benefits to NHS provided by using MIRA are mostly related to health outcomes, efficiency & cost effectiveness. Thus, MIRA can:
  • Supplement staff shortage and reduce waiting times, by enabling more patients to be treated at the same time at the clinic as well as remotely supervised at home
  • Reduce recovery time for a large group of patients by increasing motivation for the adherence to treatment through an interactive and engaging exergaming tool
  • Reduce costs associated to travel by decreasing the necessary number of visits to the clinic
  • Prevent further injury or surgery and thus reduce important costs associated to further hospitalisations and treatment caused by lack of compliance to the initial treatment
 
Quotes from NHS clients
"The [MIRA] concept is that it will replace me, as the clinician, or the therapist who is going to do the exercises with the patient. Not for all of the time, but for a part of the time. So it will supplement what we do and it will also improve patient care because patients will do it better based on the principles of gamification. When I describe it to people, people just go Wow! If this continues, it will change the way modern medicine is practiced"
Mr Bibhas Roy,
Shoulder and Elbow Surgeon, Central Manchester NHS Foundation Trust 
               
“There is huge potential. I give a lot of talks to older people and they are very interested…There is a great need there. You can have a lot of patients using the exergames at home with the physio reviewing and keeping an eye. With the data that is remotely sent to the clinic you can very easily see if individuals are complying, improving, and if they are not improving whether they need a visit.
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
“Many individuals over the age of 65 haven’t played computer games before, but those who have been helping us test the technology have given us very positive feedback.”
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
 “MIRA is an innovative product that could alter the way therapy is delivered to patients in the future. It has the potential for patients to be more active in their rehabilitation, which should result in improved patient and service outcomes.”
Mark McGlinchey,
Clinical Specialist Physiotherapist, Guy’s & St. Thomas’ NHS Foundation Trust
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Benefits for WM
  • An innovative tool that offers the possibility to have a better supervision of their patients, better medical outcomes and a more competitive practice
  • Created based on the best available clinical evidence (ex. Falls prevention exercise package) and validated in clinical trials
  • Net average saving associated with the use of Exergames for falls prevention would be £1,202 per patient per year for one MIRA unit (Health Economic Report by JB Medical)
  • The clinic can offer MIRA as a separate therapy service, developing a new business opportunity, improving treatment and physiotherapy services delivery (like reducing waiting times)
  • MIRA allows them to track patients’ compliance and progress at home
  • Reduce readmission and costs associated to further treatment and hospitalisation due to non-adherence to initial prescribed therapy (ex. Home exercises are more likely to be done if patients are being checked and if they have an engaging tool.
  • Specific therapy plans for patients can be prescribed from any location, and  it offers a suit of customisable exercises and games that therapist can easily tailor as they see fit for their patients
  • Possibility to monitor and engage more patients at the same time
  • Based on this modern instrument with its data gathering feature, therapists can access new research opportunities, important movement data and statistics that were not easily available before
  • Patient data is safe – data protection and security regulations have been carefully implemented to ensure best protection and security measures required have been implemented
Benefits for its population
  • An attractive environment through gamification engages patients to perform the prescribed exercises and comply with their treatment avoiding further complications and reducing recovery time
  • A new, easy and fun way to interact with rehabilitation or therapy
  • Patients can continue exercising in between clinic sessions being guided and supervised by a medical specialist, keeping a closer contact with the clinicians
  • Based on occupational therapy MIRA distracts the patients’ suffering and focus on pain while exercising
  • Increase the quality of patients’ life and of their families
  • When they cannot attend the therapy sessions MIRA is an efficient tool and fast way to perform the prescribed treatment plans at home
Current and planned activity: 
Current NHS Engagement:
1. Central Manchester University Hospitals NHS Foundation Trust (CMFT)
2. Guy's and St. Thomas' NHS Foundation Trust (GSTT)
3. Epsom and St Helier University Hospitals NHS Trust (ESTH)
 
Planned Activities/Upcoming:
Five other NHS organisations are in the process of implementing MIRA in their treatment delivery;

MIRA is a platform created to support extensions with new packages targeting new types of rehabilitation (hand fine movements, aerobics, speech therapy, etc.). Thus, we are willing to engage with clinical partners for clinical input, studies and validation on the development of the new modules. 

(See attached NHS Engagement document for further details)
 
What is the intellectual property status of your innovation?:
No patent on product as it is a software product (trade secret). We have full copyright of the software and source code of the application.

We are in the process of registering the MIRA trademark.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
Cosmin Mihaiu 11/04/2017 - 16:53 Publish Login or Register to post comments
6
4
Votes
-99999
Innovation 'Elevator Pitch':
Virtual Clinic is an innovative mobile app which securely sends real time patient data to the hospital database.  A web interface allows the consultant to review a patient’s condition online and give feedback to the patient.
Overview of Innovation:
Virtual Clinic enables patients to manage their conditions more effectively by communicating information about their condition on a daily basis, reducing the need to attend a clinic unless it’s absolutely necessary.



A collaboration between Imobisoft and Birmingham Children’s Hospital, the Virtual Clinic app enables patients to securely communicate information about their condition directly to a clinician while simultaneously updating the Trust’s electronic patient record system.

Currently, patients with long term conditions or requiring post-operative care regularly attend outpatient clinics. The majority of these appointments require no clinical intervention and may require several hours’ travel for what might be a very brief questionnaire-based session with a clinician.
 
If a patient’s condition changes between routine appointments, the app automatically alerts the clinician who can respond immediately and effectively, having been provided with details about the change. An intervention can be made earlier, potentially decreasing the risk of morbidity or the need for more complex interventions or hospital admission.
 
Providing patients with immediate feedback on how their lifestyle or treatment impacts on their symptoms provides immediate personalised education to help them manage their condition.
 
Virtual Clinic is a free app. Users download it onto their phone and enter their unique code to create their profile. Symptoms are recorded via slider bars and radio buttons and sent in real time to the server. Clinicians view the data received, either via an alert when abnormal data is received or by logging onto the web interface to see all data for a particular patient over a period of time. Clinicians can send a message via the web interface to the patient’s phone and run reports on patients, symptoms, etc. from the database.
 
The functionality of the app can be applied to the majority of long term conditions currently managed by regular Outpatient appointments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
Successful implementation of the Virtual Clinic app will support the health care community vision and aims by:
 
1. Adding to the communication channels between patient and consultant at the time that their chronic condition has worsened
2. Improving efficiency in clinical workflows via automatic two-way messaging between the patient’s app and the clinician
3. Providing real time clinical intelligence on a patient’s symptoms to highlight any clinical issues via alerts
4. Patients using Virtual Clinic will not have to attend regular Outpatient appointments if the condition has abated, thereby freeing up Outpatient appointment slots
5. Providing prospective data on patient outcomes, informing future patient management decisions and advances in practice.
 
The implementation of Virtual Clinic is expected to realise improvements in a number of areas:
 
• Redesigned processes associated with monitoring of chronic conditions
• Real-time monitoring when a patient’s condition worsens
• Ability to interact with a patient when their condition initially worsens, rather than at an outpatient appointment when the condition has continued to deteriorate
• Decreased Outpatient appointments
• Decreased A&E attendances and admissions with disease complications
• Improvements in information for reporting purposes via the collection of data regarding a patient’s condition
• Collection of validated prospective health status data
• Improved outcome data for audit and research
• Improved patient satisfaction.

Virtual Clinic can be customised for various metrics monitored via Outpatient appointments (e.g. incontinence, asthma, diabetes, etc.). Currently, Virtual Clinic is used for patients at Birmingham Children’s Hospital with anorectic malformations and chronic constipation.

“Virtual Clinic allows the clinician to communicate via the app with the patient and give feedback. It also allows the clinician to tailor the treatment of the patient more precisely based on his daily symptom recording and therefore adjust his follow-up in clinic according his clinical needs. By allowing the clinician to monitor a patient's condition in real time, the Virtual Clinic app has huge potential to improve patient care. I believe it will reduce the number of unnecessary Outpatient appointments, deliver significant cost savings, free up capacity and inform future advances in practice."    Mr Ingo Jester, Consultant Paediatric Surgeon, Birmingham Children’s Hospital
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
1. Imobisoft Ltd is a West Midlands based SME and adoption of the Virtual Clinic app within the region would allow the company to grow and take on additional specialist staff
2. Reduction in unnecessary Outpatient appointments
3. Improved health and wellbeing from the enablement of early intervention, potentially decreasing morbidity and preventing the need for more complex interventions or a hospital admission
4. Reduction in travel for patients (reduces pressure on the region’s transport infrastructure)
5. Reduction in the need for parents and/or carers to take time off work to escort the patient to and from hospital.
Current and planned activity: 
A pilot study is currently in progress at Birmingham Children's Hospital NHS Foundation Trust. The ROI will be available when this completed.

Other NHS engagements include:

University Hospitals of North Midlands NHS Trust
Heart of England NHS Foundation Trust
South London and Maudsley NHS Foundation Trust
What is the intellectual property status of your innovation?:
The intellectual property in the Virtual Clinic app is owned by Imobisoft Ltd.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
4
Regulatory Approvals:
Not applicable.
Investment sought:
Not applicable.
Read more
Hide details
imobisoft 12/02/2016 - 13:47 Publish 1 comment
5
2
Votes
-99999
Innovation 'Elevator Pitch':
Proven in practice with NHS Pathology Laboratories, Pathology Manager delivers complete document management  support for all pathology process and works in partnership with any existing LIMS, PAS or Order Comms systems.
Overview of Innovation:
Complete Document Management for Pathology Departments to enable access too, and the sharing of information.
A proven scanning, barcode recognition and metadata tagging system for all paper forms used across a Pathology Department with instant retrieval & viewing from a web browser and via integration with any existing Pathology LIMS plus additional options for incorporating all other paper and digitally generated documents.
Developed in collaboration with NHS Pathology Laboratories, Pathology Manager delivers complete document management support for the whole pathology process. It enables the scanning of pathology request forms & paper documents and ingestion of digital files all into one system with intelligent barcode recognition and easy application of metadata plus instant search, retrieval & viewing directly over the organisation's network and from within an existing LIMS or PAS. It is 'plug & play' and very (very) affordable.

Uniquely with Pathology Manager, all documents - scanned paper, digitally generated (e.g. Word), emails, data reports, etc - are seen together via a Single Unified View (simultaneous viewing whatever their file type). And with instant searching, filtering and reporting plus automated alerting, auditing and monitoring, full document management across all pathology activities is ensured.

Pathology Manager works in partnership with existing LIMS (Laboratory Information Management Systems) like Clinisys MasterLab or Winpath, StarLIMS and Telepath (and any PAS) in support of all the pathology processes.

For additional information on features and benefits - Please visit:
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Helping Pathology save costs
  • There is no limit to the number or volume of scans generated (i.e. there is no extra 'cost per image' as with most other scanning software)
  • There is no limit on the number of users
  • There is no limit to the volume of documents made available for search & retrieval
  • Instantly reduces paper storage space and improves process efficiency
  • Pathology Manager is significantly more affordable than any alternative whilst providing 'best of breed' features & functionality
Essentially, with Pathology Manager both the Cost of Purchase and the Cost of Ownership are significantly better than any alternative 

"Pathology Manager has allowed us to improve the efficiency, accuracy and speed of some of the key services provided by the Pathology Department.  It has provided a highly cost effective, high performance solution to a long standing information management challenge".   
Worcestershire NHS Pathology


For additional information on features and benefits - Please visit:
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • Folding Space would like to extend the use of our software across the whole of the West Midlands as this would allow us to grow and develop not only our service here in the region but also to excelerate our software development and its facilities, products and our company.
Current and planned activity: 
  • Currently selling Pathology Manager into the NHS with adoption of the product within two trust within the West Midlands region
    • Walsall Healthcare NHS Trust
    • Worcester Health and Care NHS Trust
    • North Midlands NHS
       
  • Folding Space is working in conjunction with multiple trusts to pilot and develop a new product that will be market ready in April 2016. This project has been funded by Innovate UK
Planned / required activity
  • Increased procurement / adoption of Pathology Manager within the West Midlands region
     
  • Folding Space currently have another medical product in development that will be ready for commercialisation in April, further support and interest in the product will be sought at that time
What is the intellectual property status of your innovation?:
Folding Space owns all its IPR
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:

Yes

Measures:

Revenues

Adoption target:

UK wide, commercial and public sector

Read more
Hide details
Chris Massey 29/02/2016 - 15:37 Detailed Submission Login or Register to post comments
3.3
3
Votes
-99999
Innovation 'Elevator Pitch':
e-ASPECTS automates medical imaging analysis, providing confident decisions in the treatment pathway for acute stroke patients.  e-ASPECTS automatically implements the clinical scoring methodology, Alberta Stroke Programme Early CT.
Overview of Innovation:
Brainomix’s ground-breaking technology, e-ASPECTS, circumnavigates the time lag to treatment by automatically implementing the Alberta Stroke Programme Early CT Score (ASPECTS) scoring system on brain images from acute ischemic stroke patients, to identify and quantify signs of early ischemic stroke damage and provide an assessment to support treatment decisions.

Innovation of Brainomix e-ASPECTS Stroke Imaging
The key thing to note that is that the solution is highly innovative and first to market of its kind with no comparable solution available. Our co-founders include Professor Alastair Buchan, dean of medicine at Oxford University and the inventor of the ASPECTS score, and practicing clinician Professor Iris Grunwald, interventional Neuroradiologist at Southend Hospital and one of the first physicians to be successfully performing thrombectomies in the UK. 
  • e-ASPECTS is a decision support tool that automates the clinically validates ASPECT method scoring of CT scans, providing a fast, standardized result
  • e-ASPECTS is the only decision support tool for scoring non-contrast CT scans of stroke patients using the ASPECT method - a well established stroke scoring system
  • It is CE marked and has been validated to perform as well as expert Neuroradiologists in performing ASPECTS on hyper-acute stroke patient scans
  • Multiple randomized multicentre clinical trials have demonstrated (as recently as last year) that endovascular treatment is effective, and it is set to become the future standard of stroke care (in conjunction with existing thrombolysis treatments).
  • International guidelines for the selection of patients for this treatment include the ASPECTS score for identifying ischaemic core on non-contrast CT scans
 Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up
          treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per
          patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in
          decision making is £40 of consultant time, plus £21 from reduced length of
          stay, leading to a total of £61 saving per patient. If thrombolysis uptake is               also increased by 20%, the total saving rises to £150 per patient.


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Digital health
Benefit to NHS:
Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in decision making is £40 of consultant time,
          plus £21 from reduced length of stay, leading to a total of £61 saving per patient. If thrombolysis uptake is also
          increased by 20%, the total saving rises to £150 per patient.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Better patient outcomes and treatment options.
Current and planned activity: 
We already have a number of NHS Hospitals and hospitals abroad using this solution. Once we have engaged with a Clinician who is interested in this solution we arrange to provide them with a demonstration so they understand the full benefits of the technology.
What is the intellectual property status of your innovation?:
IP is wholly owned by Brainomix. We follow a "trade secret" approach rather than patenting as we believe that this is more appropriate as it is a software device.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Deb Whitehall 26/04/2016 - 18:26 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
DLS Access gives patients same-day access to their healthcare professionals via the web/smartphone/Skype or telephone achieving savings of £15 per patient with additional benefits.
Overview of Innovation:
DLS Access allows healthcare professionals to deal with increasing patient demand more efficiently and delivers a clear return on investment.  DLS Access is a cloud based service which is purchased on an annual per patient licence basis across the whole patient population.  The service is backed-up with executive level support and access to a DLS Client Delivery Manager to ensure successful deployment into your organisation.
 
Consultation requests are made by registered patients using their phone, a smartphone app or via a web form.  All requests are directed in to the ‘Health Hub’ and handled by trained call centre operatives.
 
The Health Hub team puts each patient on a call-back list for the requested healthcare professional who then aims to call the patient back within an hour, either by phone or Skype, whichever the patient requested.  This system provides same day primary care access for the group’s patient population, without opening for extended hours.  Out of hours demand is managed better and patients are seen quicker.
 
Results from the first deployment of DLS Access, which was through their partnership with Modality (previously Vitality) Partnership in the Prime Minister’s Wave 1 Challenge Fund programme have been more than hoped for.
 
DLS Access has demonstrated a £15 saving per patient across the group.
  • Over 65% of all health concerns are now dealt with remotely, within the hour.
  • Practices within the group have seen between 5-10% reduction in A&E attendance as a result of the DLS Access Service.
  • The Group have seen a 72% reduction in missed GP and ANP appointments. 
Many other benefits have been seen across Modality’s business as well as a return on investment from the savings the DLS Access project has achieved, these are outlined in the ‘Benefit to the NHS’ section below.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Person centred care
Benefit to NHS:
Results and benefits shown below have been tracked through Digital Life Sciences’ wave 1 Prime Minister’s Challenge Fund Programme, delivered in partnership with Modality (previously Vitality) Partnership between March 2013 and 2014.  The service continues to run, with the next steps of the digital strategy to be delivered through the Modality Vanguard programme.
 
The Modality Health Hub is one of the first truly digitally delivered primary care services and the first live example of how technology is enabling 65,000 patients to access their healthcare digitally.
 
DLS Access – Results for 65,000 patients
 
  • £15.49 saving per patient
  • 1600 patient hub contacts per day
  • 40 seconds average time calls are answered with in the Health Hub
  • 1,100 downloads of the Health Hub App to date
  • 400 website users per day
  • Over 4,000 registered online users
  • 68% of all health concerns are dealt with remotely within the hour
  • 32% of all patient demand now requires a face to face consultation
  • 72% reduction in missed GP and ANP appointments
  • Reduced consultation time – an average consultation is only 5 minutes, compared to the traditional 7 minute face to face consultation
  • Increased clinical capacity – early indications show up to a 10% increase in the number of patient consultations handled each day
  • Demand for appointments equalising – demand for appointments is equalising throughout the day and week, easing the historic 8am and Monday bottlenecks
  • Increasing online requests – an average of 50 online requests received per day with 28% received via the bespoke Android and iOS mobile apps 
“The new system is improving every day as patients and staff gets used to a different way of working.  Compared to the old system, I am able to speak to a greater number of patients per day and my patients only need to visit the surgery when absolutely necessary” – Dr Shaylor, Laurie Pike Health Centre
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The return on investment calculations for a DLS One Patient Access PMCF Wave 1 project, based on 65,000 patients (costs are based on a transformed operating and workforce model that incurs no additional cost, which can be achieved with clear leadership and a commitment to change across the project.
 
Annual savings for patient population:
DNA’s based on 72% reduction £209,950.00
A&E attendance based on 18% reduction £1,186,900.00
Total annual savings for patient population £1,396,850.00
 
Cost to install One Patient Access:
One Patient Access model of £5 per patient per annum £390,000.00
 
Return on Investment (shown as savings):
Return on investment for whole patient population £1,006,850.00
Per patient ROI £15.49
 
Many other benefits can be realised such as reduced consultation time, increased clinical capacity, demand for appointments equalising and an increase in online requests.
 
More information is available – click here.
 
“Just a quick note to congratulate you on the Modality Partnership app.  Personally, I think this is a great app which has allowed me to connect very easily and quickly to my doctor” – Modality Patient (comment from Modality Partnership website.
Current and planned activity: 
DLS Access is currently being rolled out to 'at scale' primary care providers including the South Worcestershire GP Federation and Aylesbury Vale GPs. The business is actively engaged in selling the service across the NHS.
What is the intellectual property status of your innovation?:
The I.P. is wholly owned by Digital Life Sciences Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Robin Vickers 01/03/2016 - 15:23 Publish Login or Register to post comments
6
4
Votes
-99999
Innovation 'Elevator Pitch':
Whose Shoes?® is much more than a ‘board game’ or training. Through a range of scenarios and topics, Whose Shoes?® helps you explore the concerns, challenges and opportunities facing different groups affected by health and social care transformation
Overview of Innovation:
Whose Shoes? is a popular approach to co-production within the NHS, endorsed and actively supported by the Patient Experience team at NHS England and the Transformation team within NHS Improving Quality, as well as local authorities, universities and other public services. It is a flexible tool that can be adapted (through bespoke partnerships) to a wide range of topics and challenges. The original board game, launched in 2008, explored issues around the emerging personalisation agenda.
A person-centred and values-based focus remains central to all development.
New material is being developed through strong collaborations with passionate people, fired by a very strong social media presence and networking capability. Whose Shoes looks at issues from different perspectives and triggers crucial conversations, with real ‘light-bulb moments’ as participants come together as ‘people’ rather than roles and work together to find solutions to the issues that matter to them. Getting as wide a range of participants as possible around the table cuts across boundaries and flattens hierarchy.
The relaxed approach creates the conditions for ‘service users’ to contribute as equals in a relaxed environment which is conducive to open, honest exchanges. People are empowered to lead rather than simply contribute. There is a strong focus on action and sharing good practice widely, with participants encouraged to make pledges and to share good practice through stories and case studies and to promote these through social media. Graphic recording of Whose Shoes workshops is very popular with hospitals using the records as action plans.
The maternity version of Whose Shoes? has been developed in partnership with the London Strategic Clinical Network and NHS England. It was piloted in five London hospitals. Workshops are now spreading – including other London hospitals, Guernsey, Leeds, Cumbria and Manchester.
Whose Shoes? material to improve communications between children and young people, their parents and healthcare professionals has been co-produced with Great Ormond Street and HENCEL.
Scenarios to promote dementia-friendly communities and understanding by NHS staff of the challenges of living with dementia have been produced through partnerships with Skills for Health and an Age UK consortium. Integration scenarios are used in the Darzi programme. Bespoke scenarios around other areas of patient experience (e.g operating theatres) is being trialled with Kingston Hospital
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
“ Whose Shoes brings people together to have conversations that matter, the resources stimulate thoughts which lead to new insights & importantly to actions through the power of human connection & the use of narrative. ..... The energy generated is tangible .......it’s sustained long after as the creativity of both the public and professionals in unleashed. I’d really recommend the approach as a vehicle for any service committed to ongoing improvement
#Hellomynameis… Kath Evans, Experience of Care Lead (Maternity, Infants, Children and Young People), NHS England
 
“ ‘Whose Shoes’ has been an incredible catalyst in Maternity care. Having set up 5 pilot workshops with the London maternity strategic clinical network there has been a tremendous ripple out to hold further workshops in other Trusts as well as the phenomenal change platform that is #MatExp.
The actions are far to numerous to list here, some examples: a  graffiti board …to give live feedback on services, decorating the maternity theatre ceilings to improve the environment for women undergoing Caesarean section (CS), optimal cord clamping ……. midwifery workshop to explore better collaborative working - the list is endless.
We have also used ‘Whose shoes’ in other areas of the hospital with success #KHFTWhoseshoes, improving  staff attitude & environment and patient experience in our main operating theatres & having a drop in session on administration at our Trust Open Day”.

Florence Wilcock, Consultant Obstetrician Kingston Hospital NHS Foundation Trust, Chair of the London Maternity Strategic Clinical Network maternity experience subgroup.
 
"Whose Shoes is a creative opportunity to engage staff, women and patients in a process of improvement and enlightenmen, The #MatExp social movement for change ... used in our failing maternity service to better understand the experiences of women, their birth partners & our staff.  The creative energy & ideas generated during our session were directly developed into practical actions & we have subsequently used the model of engagement in other clinical areas.  Whose Shoes played an important part in our improvement journey & is having a direct impact on outcomes for women, birth partners and staff"
At the time of engaging with Whose Shoes, Steve Hams ex-Interim Dir. of Clinical Governance & Chief Nurse for the Health and Social Services Department at the States of Guernsey, now Interim Dir. of Clinical Performance & Delivery, NHS Surrey Downs CCG
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
It feels currently as though the West Midlands is largely missing out on what is now a popular, proven improvement methodology being adopted rapidly in other parts of the UK and now reaching out internationally. This tool is very different from the ‘same old’ , traditional ‘top-down’ consultation models. It is about real staff and patient engagement leading to rapid improvements – and people find it fun too!

The NHS benefits would be similar to other parts of the country but it would be easier and cheaper (travel, accommodation) to work in partnership with West Midlands (ie local) NHS Trusts / CCGs.

Also New Possibilities, the recommended graphic facilitators, with whom we work as very close business associates, are based in Birmingham.

Thus greater adoption in addition to helping, patients and helcare providers it would also allow our regionally based company to grow and develop new specialised products as well exporting this delivery process overseas e.g Currently exploring taking 'Whose Shoes Maternity' approach to Uganda.

Currently Adopted / Procured by:
  • NHS England: North region; East Midlands
  • Hospital Trusts include:
    • Kingston, Guy’s and St Thomas’s, Lewisham & Greenwich, King’s College, UCLH, Leeds, Croydon, Maidstone & Tunbridge Wells, Stockport, Manchester, NHS Cumbria, North Cumbria
  • Cheshire & Wirrall Partnership Trust
  • Guernsey HSSD
  • Great Ormond Street (partnership - CYPMeFirst masterclasses)
  • CCGs include: West Leicester, West Kent, Leeds
  • AHSN / Area Team: Wessex, Thames Valley
  • International workshops and talks delivered: Australia, Malta, France; Puerto Rico

See: www.nutshellcomms.co.uk for 'Case Studies' and other information.
Current and planned activity: 
  • Building on 5 pilot workshops (& Train the Facilitator session) carried out with NHS Eng. & the London Strategic Clinical Network supporting the new maternity experience; now spreading to hospital trusts across the UK
  • 12 Whose Shoes #dementiachallengers in March 2016 workshops across Kent, Surrey and Sussex, run by Age UK consortium, commissioned by HEEKSS
  • On-going partnership with Great Ormond Street Hospital to use bespoke scenarios in #CYPMeFirst masterclasses for multi-disciplinary health professionals working in paediatric services from many hospitals; the first 20 ‘Communications Champions, who are taking this into their own organisations; more being recruited (up to 100)  
Required activity
  • Procurement / Adoption of Whose Shoes? -  Across the W Midlands NHS Trusts, via workshops or via purchase of online/board game versions of Whose Shoes?
  • Collaborative work to personalise Whose Shoes? For particular projects or departments
What is the intellectual property status of your innovation?:
Design registered. UK Registration Design No. 4009563; Trade Mark (Whose Shoes): No. 2502651
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Gill Phillips 29/02/2016 - 17:31 Publish Login or Register to post comments
5
2
Votes
-99999
Innovation 'Elevator Pitch':
Medelinked is a secure mobile and online health platform that empowers you to take control of your health and sharing your health and wellness information with your trusted healthcare providers.  
Overview of Innovation:
Medelinked is leveraging mobile technology and the cloud, aiming to increase health care efficiency and effectiveness. Medelinked Health Cloud and API is the leading platform already powering some of the best mHealth applications allowing developers to create a series of new applications that deliver real health benefits to the end user and healthcare professionals. 
Using Medelinked, individuals are able to create a health profile online that is secure and connect and share their health record with their network of trusted health partners and providers (including doctors, dentists, physiotherapists, trainers, insurers, clinical researchers). Managing all their health data in one place helps individuals securely track and monitor improvements easier and quicker and share vital data with their healthcare providers to ensure they have access to their latest health data. This enables them to provide the best possible care and it keeps the individual in control of their own health.
Medelinked Account Features:
  1. Add key personal details and list medical conditions, medications, allergies and vaccinations, together with your next of kin details
  2. Add contact details for all the important health professionals you interact with in order to communicate directly with your GP, receive health advice in real time and chat by secure email, voice, text, video and instant messaging.
  3. Create an emergency record that can then be accessed by emergency first responders with its needed most
  4. Upload and store scans, x-rays and other medical reports and test results
  5. Connect your health devices (smartwatches, fitness trackers, blood pressure monitors and blood glucose monitors) to enable seamless streaming of data into your account. Set alerts, monitor and share progress with your support network
The benefits of a Medelinked account is that it allows the patient record to travel with the patient and with this innovation a number of benefits follow. We anticipate better clinical outcomes, greater co-ordination, fewer adverse incidents and cost savings for the NHS as a result of better adherence and compliance with drug regimes, early recognition of signs of illness and increased patient engagement. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Person centred care
Benefit to NHS:
Cost savings will be derived via better adherence and compliance with drug regimes, greater awareness of health status through inputted data, early identification of illness, ease of communication with health professionals.
Medelinked helps meet the requirements of the accessible information standard and enables a paperless NHS.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Medelinked information sharing approach restores trust by placing control in the hands of the consumer.
Managing health data all in one place helps individuals securely trace, monitor and improve their health state, ensuring their latest health data is accessed and enabling the provision of best possible care,
Personal health records allows the patient record to travel with the patient, allowing better clinical outcomes and fewer adverse incidents.
Current and planned activity: 
Medelinked to date has not tried to work with the NHS. The companies focus has been to work with private health insurers and to offer a free to the consumer platform. We know that many consumers are now using Medelinked and asking to link to NHS suppliers. We would like to break down this barrier for our users. 
What is the intellectual property status of your innovation?:
Owned by Medelinked 
About us
Since 2005 Medelinked (previously Zaptag) has been delivering a range of solutions for building, connecting and sharing personal health information. We currently deliver solutions for private health insurers like Aviva, Simply Health and IntegraGlobal. Our open platform and partner approach allows us to deliver bespoke white labelled solutions. Major integrated partners also include Salesforce, FitBit, BioClinica, Allscripts and Jawbone.

Medelinked is based in Oxfordshire, UK. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Mary Wilson 08/11/2016 - 16:03 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
We have developed a clinically led digital health solution for warfarin patients at risk of stroke. Our technology enables patients to self-test from their own homes with remote clinical support, communicating their INR in a way that suits them.
Overview of Innovation:
Our INR self-testing service has been rolled out to 5,000 patients, making it one of the largest in Europe. Across the UK, patients on the service are remotely monitoring their INR away from the clinic using a Roche CoaguChek® device. Readings are sent to their nurse via an automated phone call or by logging onto an online portal. Readings automatically go through anticoagulation software where the next dose is determined. A clinician approves the next dose and the patient receives a second form of communication, either an automated phone call or an email informing them of their next warfarin dose and date and time of next test. Find out more here http://www.inhealthcare.co.uk/product/inr-self-testing/.
Our self-testing study concluded patient’s therapeutic range (TTR) improved by 20% for 70% of patients. In comparison a controlled cohort of clinic based patients had seen only 49% of their cohort improve by an average of 2%.This improved TTR predicts to save 400-500 strokes per year.” – Ian Briggs, Associate Director of Business Development, County Durham and Darlington Foundation Trust.

To find out more about INR self-testing in County Durham and Darlington Foundation Trust download our case study here http://www.inhealthcare.co.uk/resource/county-durham-and-darlington-nhs-foundation-trust/.

The service has also been rolled out in Wigan, Ilkley and the Isle of Wight. Read this blog from our CEO Bryn Sage about INR self-testing in the Isle of Wight http://www.inhealthcare.co.uk/isle-of-wight-are-leading-the-way-with-inr-self-testing-for-warfarin-patients/.

Outcomes:
  1. Improved patient outcomes: In a recent 24 month follow up study from County Durham and Darlington Foundation Trust we found over 70% of those on the service improved their time in therapeutic range by 20%.
  2. Improved patient satisfaction: The service is quick and easy to use. Patients do not have to take time out of their day to attend appointments and aren't bound to NHS opening hours. 100% of those surveyed said they'd recommend the service to others.
  3. Increased efficiency: Enabling patients to self-test enables resources to be distributed elsewhere.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  • Reduced workload
  • Increased capacity
  • Cost savings
  • Able to spend more quality time with patients that need to attend the clinic
  • Access to real time patient data
  • Able to identify any adversities and make changes in treatment much sooner
  • Able to make informed decisions around patient care
  • Choice of communication method to suit their patients
Initial Review Rating
5.00 (3 ratings)
Benefit to WM population:
  • More flexibility for patients
  • Improve clinical outcomes
  • Not bound to NHS opening hours
  • Able to find out more around condition
  • Less clinic visits and associated costs
  • Technology is quick and easy to use
  • Clinicians have access to a continuum of data meaning patients don’t have to repeat themselves during appointments
Current and planned activity: 
We are currently working with a number of NHS organisations that have implemented our INR self-testing service including County Durham and Darlington NHS Foundation Trust, Wigan Borough Federated Healthcare, Isle of Wight CCG, Ilkley Moor GP practices.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Lauren Ramsey 24/05/2016 - 14:20 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Sensely Ask NHS mobile app offering is a virtual nurse, Olivia, who guides the patient through clinical triaging or long term condition monitoring. Integrated and working with the NHS workforce. 
Overview of Innovation:
'Ask NHS' powered by Sensely provides patients and clinicians with improved access to NHS 111 and their local NHS services. Patients can talk through your symptoms in complete confidence with Nurse Olivia, a virtual nurse. If needed, Olivia she will arrange for a call back from a 111 Nurse to discuss symptoms further. Patients can also search NHS approved healthcare advice, schedule GP appointments and search opening times/locations of local healthcare services. It's the link for improving patient experience with Healthcare Providers and helping to cope with patient demand. Our key value proposition is to automate tasks for providers. We are Trusted , Empathetic, Personalised, Mobile First.

Sensely offers

- Mobile application platform that engages in natural conversations with patients.
- A clinician facing product which is data and process driven patient risk assessment.
- Direct Appointment Booking with GPs
- Service Locator (Integration with the NHS Directory of Services)
- Self Care Advice. Easily search through trusted NHS Choices healthcare advice and resources to gain a deeper understanding of conditions and treatments.
- Triage and Integration with Clinical Hubs (inc. NHS 111)
- Chronic Disease Management (CHF, COPD, Diabetes)

Olivia, our virtual nurse is connected with patients - 24/7 via their mobile device. She can help by answering their medical questions , measure their blood pressure, weight or glucose via blue tooth device, take a picture of their rash or swollen ankles and ask triage questions integrating with primary care services.

Olivia has been designed to embody the bedside manner of real healthcare professionals, and to be the clinician’s presence in patient’s life 24/7. Most importantly she does not only act as your virtual nurse - collecting vitals, scheduling appointments, offering health and wellness advice - she acts as your constant stream of accurate and clinically triaged information.

'Ask NHS' is powered by Sensely and delivered in collaboration with the NHS, NHS 111 and Odyssey by Advanced Healthcare. Visit http://www.sensely.com/asknhs to learn more.

For more information visit : http://www.asknhs.co.uk/ or email us at nhs@sensely.com
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Key Benefits

1) Saving the Clinician time. Pre Appointment Triage / Screening of patients, helping to prioritise those who need to be seen urgently - acting as admission avoidance tool. Sensely also offers the ability to directly book / cancel appointments into EMIS Web practices helping users to make an appointment when needed. Sensely supports CCGs achieve patient online programme initiatives through collaborative working we're providing the complete solution - one bundled app to navigate UK healthcare.

2) Improve health data. Using data captured through wearables. Sensely helps capture data and readings e.g blood pressure and weight measurements which can be subsequently filed to the GP patient record. Through the use of GPSoC APIs - data is recorded in a standard format using Readcodes ensuring high quality data capture and future analysis.

3) Using Sensely on smartphones provides clinicians with an ever-present clinical decision support tool that ensures they are providing patients with the best care plans.

4) Improved Patient Care - 24/7. Always available. Users can use the app to monitor their health and understand their body better. Subsequently, through Senselys integrated offering - the platform can alert a clinician when a patient who is being remotely monitored is flagged at being at risk. In the US - Sensely is used for supporting Chronic Care Management.

5) Improved efficiency to urgent care delivery. NHS 111 currently receives approx 30,000 calls per day. At an average of £13/call. This equates to £390,000 per day. Through the use of Sensely Artificial Nurse - we believe we can deal with a percentage of the self care queries / calls which are dealt with by a non clinical advisor (approx 20%) for which we could help save the NHS a potential of £78,000 per day.

6) Sensely interfaces with the Directory of Services which is utilised by NHS 111. Through the use of Service Locator - both clinicians and public can locate the right service at the right time. The tool ensures visibility of new services is transparent as possible to the right user. It is simple to use, accurate - always available tool where the content is locally administered by commissioning dos leads.
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
To solve the health industry operational problems, we created Sense.ly. Sense.ly is a mobile-first application platform that engages in natural conversations with patients to educate them, assess their medical conditions, answer their questions, and find the best possible sources of virtual assistance, telemedicine, or facility assistance. Our technology gives health providers and insurance companies the power to tailor unique customizable communication protocols and interaction workflows for each patient. The product offers the following capabilities:

1. Provides patients with a high quality “mobile virtual assistant” that proactively and reactively engages people in natural, personalized conversations and educational topics depending on their status, historical, and current issues.

2. Continuous monitoring of patients via mobile app

3. Connects patient/provider/payers with secure telemedicine and SMS platform

4. Delivers clinical, educational, and NHS/CCG information directly to the patient based on daily clinical picture, stage of treatment, claim progress, and immediate needs

5. Analyzes health data to calculate clinical improvement, compliance, readmission risk, and patient engagement.

6. Analyzes data-aggregates across disparate populations for the purposes of machine learning, disease prevention, risk/cost management, and clinical trials. Doctors and specialist use the information Sense.ly provides to optimize their team’s workflow around patients requiring immediate attention, while freeing up resources that would otherwise be allocated to less demanding cases.
Current and planned activity: 
Concept/Idea (No prototype, wireframes): Prescription Ordering

Working prototype developed (gathering feedback): Service Locator, Self Care, Direct Appointment Booking

Prototype with pilot users/clinical trials (test/validating): NHS 111 Odyssey Assessment integration with NHS 111, Medication Check

Prototype with paying customers: Patient Kiosk, Daily Check In

Fully developed product (paying customers, renewing contracts): Chronic Care Management
What is the intellectual property status of your innovation?:
The IP include 7 patent applications allowing us freedom to continuing to operate and innovate on our products and service lines by refining
our proprietary avatar conversation engine and clinical decision support system. The IP includes code, methods, and integrations defining the
conversation engine.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Anonymous 21/09/2016 - 14:58 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Smartinhaler™ is an innovative electronic medication sensor that improves suboptimal medication use in patients with chronic respiratory diseases, including asthma and COPD. Our current focus is in asthma.
Overview of Innovation:
Poor medication adherence is one of the leading issues in the management of asthma and is thought to account for 34% of all asthma deaths (Royal College of Physicians, 2014) and treatment adherence to inhaled corticosteroids could reduce hospitalisation by 60% (Williams et al., 2004).
Smartinhaler™ (by Adherium Ltd) is a digital health solution to improve medication adherence in patients with chronic respiratory diseases. This is how it works: Smartinhaler™ clips onto an existing prescription inhaler. Once installed, the Smartinhaler™ device (1) periodically remind patients to take their medication, (2) records the date and time of inhaler use (independent of patient action), (3) transmits patient usage data to a mobile device and into Adherium’s cloud-based servers for patients and/or clinicians to review, and (4) provides warnings when the data indicate the patient’s disease may be escaping control.
The benefits of the Smartinhaler™ have been validated by independent clinical research. Four randomised controlled trials have shown consistent improvement in asthma medication adherence, ranging from 144% to 180% in children (Chan et al., 2015; Morton et al. 201X) and 33.3% to 58.7% in adults (Charles et al. 2007; Foster et al., 2014). Subsequently, the three studies measuring clinical outcome have demonstrated improved patient health as indicated by a reduction in oral corticosteroid use, reliever medication use, emergency room visits, lost school days and asthma morbidity score (Foster et al., 2014; Chan et al., 2015; Morton et al., 201X).
Audiovisual reminders markedly improve adherence to inhaled corticosteroids and thus increase health outcomes, whilst tracking reliever use may allow early detection of severe exacerbations (Patel et al., 2015). Furthermore, the objective nature of electronic adherence data enables an open and honest discussion about adherence and the barriers encountered by the patient. In turn, through HCP (or parental) intervention, this results in practical solutions to better manage asthma and or COPD.
The Smartinhaler™ platform was designed with patients in mind. In the development of the Smartinhaler, we’ve consulted patients and medical professionals to produce a user-centred system that facilitates good medical practice as well as empowering the patient.
For a list of references please visit our website: http://www.smartinhaler.com/outcomes/
 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential reduction in mortality, hospital admissions, hospitalisations and A&E visits: Asthma accounts for approximately 60,000 hospital admissions and 200,000 bed days a year, with many others visiting A&E clinics without stay, uncontrolled asthma places a significant burden on NHS (British Lung Foundation, 2016). Williams et al. (2004) suggest adherence to inhaled corticosteroids could reduce hospitalisation by 60%. Given Smartinhaler’s ability to significantly and consistently improve adherence, it is expected that implementation of Smartinhalers™ will reduce the burden on the health services and most importantly improve the quality of life for asthmatics.
Potential reduction in medication wastage: In the UK, more than £230 million worth of asthma medicines are returned to pharmacies every year with a significantly larger proportion thought to be disposed by the patients themselves (Horne, 2006). Smartinhalers™ may reduce this wastage by improving treatment adherence as well as facilitating an open discussion about treatment between the clinicians, parents and patients.
Currently, the only similar technology implemented by some NHS funded hospitals is Florence – a telehealth application that connects patient data to healthcare professionals and text messaging to encourage positive behavioural change in patients with chronic illnesses. Although medication reminders can be sent to the phone, it appears text message reminders are less effective than direct device reminders (such as those in the Smartinhaler™) (Strandbygaard et al. 2010; Petrie et al. 2012). Furthermore, objective data about medication adherence cannot be collected using Florence and thus does not allow data-based clinical decisions for asthma. To our knowledge, there is no similar or equivalent technology used in current NHS practice specific for asthma. Standard physician care, asthma action sheets and for children, parental care, is the extent to which asthma medication adherence is addressed by the NHS. The Smartinhaler™ device would work alongside the current systems, used as an additional tool to improve the health of asthmatics, seamlessly integrating with current NHS practice.  
 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Asthma is a major health issue in West Midlands. West Midlands (and South East) had the highest mortality rate for asthma. Furthermore, West Midlands has one of the highest asthma-related hospital admissions in England; in 2008-12, West Midlands was considered one of the worst five regions of England for asthma related admissions; other regions included North East, North West, and Yorkshire and the Humber (British Lung Foundation, 2016). Asthma not only influences health, it is associated with significant cost to society including work and school absenteeism as well as loss of productivity while at work (Bahadori et al. 2009).  
Taken together, introducing innovative and cost-effective digital health solutions is pivotal to the improvement of the health of West Midland’s asthmatics in increasing the quality of life, reducing burden on health services, and increasing economic productivity. As such, the implementation of Smartinhalers™ is a step forward for West Midlands health care system to alleviate the burden of asthma. 
REFERENCES
Bahadori et al. (2009). Economic burden of asthma: a systematic review. BMC pulmonary medicine, 9(1), 1.
British Lung Foundation (2016). Retrieved from https://statistics.blf.org.uk/asthma
Current and planned activity: 
  • Expansion of clinical data: several large and small clinical trials using Smartinhalers in asthma and COPD are on-going or in the prepublication stage. We expect more clinical trial results to be published this year and in the years ahead.
  • Development of new devices and further improvement of existing devices
  • Further improve patient-centred design of the Smartinhaler’s user interface
  • Expansion of global regulatory approvals
What is the intellectual property status of your innovation?:

Adherium has various patent protection in numerous jurisdictions. Furthermore, we hold numerous trademarks and registered design rights for our Smartinhaler™ range.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
John Tarplee 05/07/2016 - 12:03 Publish 2 comments
5.5
2
Votes
-99999
Innovation 'Elevator Pitch':
TeleTracking provides solutions and services that enable the highest quality of care delivery and coordination, driving access, throughput and flow from the community to the acute setting to post-acute care.
Overview of Innovation:
TeleTracking equips healthcare organisations and care providers with the IT and innovation tools needed to coordinate care across the patient’s journey. Our operational platform and services combine proprietary technology with deep domain knowledge on patient flow and healthcare operations to drive access, capacity and flow from the community to the acute setting to post-acute care. 

Through a centralised coordination centre model, TeleTracking’s IQTM Platform provides real-time visibility across networks of care, ensuring patients are cared for in the right place at the right time with the right resources. 

By providing healthcare organisations with functional and technology-driven capabilities, hospitals are able to utilise real-time and historical data for continual operational improvement and organisation intelligence, leading to a better quality of care. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Benefits of an Organisation-Wide Coordination Centre: https://www.youtube.com/watch?v=M-bQhLmoi2A&feature=youtu.be
With TeleTracking’s IQ Platform, efficiency starts with a centralised coordination centre that creates transparency across care networks to enable precision patient placement from the community to the acute setting to post-acute care. Effectively providing the right bed, the first time, every time.

Often referred to as a ‘Mission Control’ Centre, an operational management platform provides a motion picture for healthcare organisations with real-time visibility to patients, beds, assets and staff across the care network. 

Areas of Impact
1. Access: Admissions, transfer and referrals, surgical case growth, left without being seen, A&E diversions, patient pull times
2. Throughput and Flow: Auto-discharge efficiency, patient pull times, A&E and recovery hold times, admissions, discharges per bed, utilisation rates
3. Care Support & Logistics: A&E wait times, patient and caregiver interaction, better patient experience, communication of infection status
4. Labour Productivity: Care support performance, nursing time at bedside, housekeeping performance, portering efficiency
 
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
TeleTracking's platform would improve patient access to care in the WM region. The WM population would get access to safe and high quality care through reduction in A&E wait times, elective cancellations, and lenght of stay.
Current and planned activity: 
TeleTracking works with over 27 NHS trusts and private healthcare organisaitons in the United Kingdom to improve quality of care through improved access, throughput and flow. Lord Carter’s report “Operational productivity and performance in English NHS acute hospitals: Unwarranted variations,” found vast inefficiencies across the NHS, with particular focus on staff productivity, poor patient flow and lost bed capacity due to bed-blocking. TeleTracking’s operational platform, under the SafeHands programme at The Royal Wolverhampton Hospitals NHS Trust, was featured in the report on page 63 to highlight the use of technology to enable operational efficiencies.
What is the intellectual property status of your innovation?:
Founded in 1991, TeleTracking Technologies has developed proprietary tools to automate healthcare operations and patient flow. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Gabrielle Zamagias 16/02/2016 - 15:56 Publish Login or Register to post comments
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Integrate with PAS and rostering systems, to bring together capacity and demand; automating manual processes used to judge which staff ought to be scheduled to which patient appointments with dynamic rescheduling throughout the day via mobile app.
Overview of Innovation:
NHS community services are one of the last industries to adopt an automated and intelligent appointment scheduling system to help manage their field based (community healthcare) staff. Significant improvements can be made in the way community workforce are managed by optimising the patient appointment booking (scheduling) process.

Initial research indicates that there are few Trust with systems in place to effectively and efficiently schedule which staff should visit which patients at which times. Our objective is to work with NHS Community Trusts to develop MISS (Malinko Intelligent Scheduling System) to systemise the current informal and ad-hoc processes used to do this.

Malinko is a scheduling system with mobile app to allow staff to check in and out of visits which is already used in other sectors.  It requires some additional work to ensure that it works well for the healthcare sector.  These elements are:
  • Integration with the PAS (Patient Administration System) to bring in patient appointment requirements and with the rostering system to for staff capacity.  By taking this information, along with predefined parameters based on provided KPIs, Malinko’s scheduling algorithm will ensure that the rostered staff attend the optimal visits.
  • Mobile app to enable staff to communicate live back to the main system any issues that would result in their visits to require rescheduling that day. The Malinko system would then automatically reschedule these and let any affected staff know. 
  • The office staff have a live nurse tracker board, enabling them to see last known locations of all nurses out in the field.
  • The nurse can send a text message or voice message to the patient to let them know they were on their way to avoid DNAs (Did Not Attends).
This would enable substantial productivity gains and cost reductions within NHS community services with marked reductions in non-clinical contact time as Nurses on average spend 19% time in administration includes office visits. It would also result in significant service improvements being achieved as it would allow community nurses to both spend more valuable time with patients and enable them to see more patients.  In turn, we would expect to see a reduction in acute activity and pressures.  Additionally, by optimising the appointment booking process there is an opportunity for NHS Community services to make direct cost savings in area’s such as travel, administration, staffing and the costs associated with DNAs.

Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Digital health / Innovation and adoption
Benefit to NHS:
Integration with the PAS and the staff rostering system into the MISS to intelligently create the appointment schedules has a whole range of benefits for the NHS provider and patients.  In summary:
  • Improve caseload management using skills, knowledge and training to best effect.
  • Help release and focus capacity due to ‘live’ organisation wide view of demand and capacity.
  • Reduces time in morning meetings at start of day as these can be electronically received by staff.
  • Automatically scheduling based on an algorithm, reducing staff scheduling time and leaving them to just approve and make manual alterations to this schedule.  
  • As referrals come in during the day, they are automatically added and scheduled dependent upon priority.  If they require a visit within the day, the system will automatically add the job onto the most efficient round and dynamically reschedule other appointments effected.
  • Route optimisation, reducing time spent travelling and cost of travel.
  • Automatic mileage expense claims based on these routes.
  • Release time to care improving patient and staff experience.
  • Patient feedback mechanism to report satisfaction with the service.
  • Analysis of patient/community nurse combinations - eg where a patient dislikes a particular nurse and so is regularly out for their visits
  • Ability to send telephone and text alerts to patients reducing likelihood of DNA and leading to improved timeliness of visits including administration of medicines. This will also result in giving patient a narrower window of likely nurse arrival.
  • Ensure prioritisation of patients that need to be seen today and those that can be deferred.
  • Ability to redirect workforce to high risk patients in an emergency, therefore preventing admissions.
  • Ability to provide continuity of care as system logs number of previous visit during allocation process.
  • Benchmarking performance across the team members or indeed whether the team as a whole is underperforming against an external benchmark with full visit history for each patient and by each staff member. Spot trends and improve resourcing.  Examples include identifying where a patient doesn’t like a particular nurse and so is regularly out for their visits, or to quickly identify training needs where staff are regularly underperforming for particular types of visits.
  • Lone worker risks prevented with mobile app and nurse tracker board.  Silent panic alarm button within the app can send to office or escalate to emergency services.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
MISS can help the NHS to deliver better care at a lower cost by freeing up capacity to meet ever increasing demand.
 
Based on in-depth research on site with 4 NHS Trusts, West Midlands NHS Community Service providers can reduce the following by deploying the MISS:
 
Reduce senior nursing non-clinical contact time: It is forecast a service/locality with 20 FTE staff, with one locality manager and two senior triage nurses, could reduce 109 hrs/month of senior nursing non-clinical contact time by automating the patient allocation process with MISS (3.6 hrs per day of senior nursing time 7 days per week; service running at 50% at capacity the weekend).
 
Reduce Community Nursing/HCA non-clinical contact time: It is forecast a service/locality with 20 FTE staff and 16 community nurses/HCAs could reduce 416 hrs/month of non-clinical contact time (1 hour a day per nurse - 7days a week; service running at 50% capacity at the weekend).
 
Reduce DNA rates by 50%: Although one Trust we have worked with reported a DNA rate of 10%, we have little hard data with regard to current DNA rates and the cost of each DNA to the Trust, the view is DNA rates could be significantly reduced by adopting MISS’s integrated automated patient appointment reminder system (text and voice calls). Other NHS Trusts have analysed how much each DNA costs, reporting an average of £80 per DNA. Reducing DNAs would also have a significant impact on improving the efficiency of the service/locality and reducing patient complaints.
 
Other potential cost savings include (more detailed analysis required): Overtime; Bank and Agency; Travel; DNA; Replace incumbent standalone lone worker system in two of the Trusts; Replace current standalone expenses system; Admin.
Current and planned activity: 
Nov 15: 1st NHS customer 

Nov 16: Agreement from GM NHS Trust to deploy MISS in their District Nursing service across 6 localities and their District Nursing evening service, pilot funded by the GMAHSN Momentum bid. 

Dec 16: Other pilot start; deploy MISS in their District Nursing service in two localities.

There are a number of other NHS organisations who are interested in MISS.  We are looking for further pilots or early adopter profile Trusts, which due to recent funding we are able to part fund internally.

We would like introductions to (Deputy) CIO or (Deputy) DOF roles within West Midlands and nationwide to NHS Trusts which provide community services, including mental health.
What is the intellectual property status of your innovation?:
The IP is held within Liquid Bronze.
Accredited with Information Governance
Accredited with ISO27001
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Antony Quinn 20/01/2017 - 17:49 Publish Login or Register to post comments
4
1
Votes
-99999

Recent Activities

Our £1.8m savings pilot has been moved from Initial Submission to Publish 3 weeks 14 hours ago
My Diabetes My Way: A Patient Support Platform for those with Diabetes has been moved from Initial Submission to Publish 3 weeks 5 days ago
IoT solutions for Integrated Health and Social Care Technology has been moved from Initial Submission to Publish 2 months 2 weeks ago
Biobanking Management Software - MbioLIMS has been moved from Initial Submission to Publish 3 months 1 week ago
Amplitude ​pro enterprise has been moved from Initial Submission to Publish 3 months 2 weeks ago

Active Campaigns